LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis
International Journal of COPD2017Vol. Volume 12, pp. 907–922
Citations Over TimeTop 1% of 2017 papers
Gustavo J. Rodrigo, David Price, Antonio Anzueto, Dave Singh, Pablo Altman, Giovanni Bader, Francesco Patalano, Robert Fogel, Κonstantinos Κostikas
Abstract
The greater efficacy and comparable safety profiles observed with LABA/LAMA combinations versus LAMA or LABA/ICS support their potential role as first-line treatment options in COPD. These findings are of direct relevance to clinical practice because we included all currently available LABA/LAMAs and comparators, only at doses approved for clinical use.
Related Papers
- → Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD(2018)1,224 cited
- → Dual bronchodilator therapy for chronic obstructive pulmonary disease(2017)10 cited
- → Additive Effect of Inhaled Corticosteroid (ICS) On Patients with COPD Receiving Long-Acting Muscarinic Antagonist (LAMA)/Long-Acting Β2-Agonist (LABA): A Single-Center Observational Study(2020)1 cited
- → Combined corticosteroid and shortacting bronchodilator in one inhaler for chronic obstructive pulmonary disease(2002)
- Duaklir Pressair: another LAMA/LABA inhaler for COPD.(2019)